Nasdaq

Alterity Therapeutics Announces Positive ATH434 Phase 2 Trial Results in Multiple System Atrophy Led By Robust Clinical Efficacy

MELBOURNE, Australia and SAN FRANCISCO, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing ...
Mena FN

Alterity Therapeutics Data Presentations Support Advancement Of ATH434 Into Phase 3 In Multiple System Atrophy

(MENAFN- GlobeNewsWire - Nasdaq) – Alterity's novel imaging and biomarker approach positions the Company at the forefront of clinical research in MSA – – End-of-Phase 2 FDA Meeting on track for ...
Medscape

Novel Iron-Lowering Drug Tied to Slowing of Multiple System Atrophy Progression

HONOLULU — A novel “moderate-affinity iron chaperone” known as ATH434 (Alterity Therapeutics) may slow disease progression in patients with multiple system atrophy (MSA), new research suggested. The ...
Medical Xpress

'Garbage collectors' of the brain grind to a halt in fatal multiple system atrophy

Multiple system atrophy (MSA) is a rare and fatal brain disorder with no available treatment or cure, attacking the nervous system, balance, and the ability to move. The disease in many ways resembles ...